Inactive Instrument

Zynerba Pharmaceuticals, Inc.

ZYNE

US98986X1090

Biotechnology & Medical Research

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from Russell 3000E Growth Index

June 24, 2022 at 12:00 am EDT

Latest news about Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index	23-10-12	CI
Harmony Biosciences Holdings Completes Acquisition of Zynerba Pharmaceuticals	23-10-11	MT
Harmony Biosciences Holdings, Inc. completed the acquisition of Zynerba Pharmaceuticals, Inc..	23-10-09	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index	23-09-28	CI
Harmony Biosciences Says its Xylophone Acquisition Unit Extends Tender Offer for Zynerba Pharmaceuticals to Oct. 10	23-09-27	MT
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
Canaccord Genuity Downgrades Zynerba Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1.11 From $10	23-08-16	MT
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Downgrades Zynerba Pharmaceuticals to Neutral From Buy	23-08-15	MT
Health Care Up on Drug Developments -- Health Care Roundup	23-08-14	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	23-08-14	MT
Sector Update: Health Care Stocks Higher on Monday Afternoon	23-08-14	MT
Top Midday Gainers	23-08-14	MT
Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Acquisition Deal	23-08-14	MT
Sector Update: Health Care Stocks Edge Higher Premarket Monday	23-08-14	MT
Sector Update: Health Care	23-08-14	MT
Transcript : Harmony Biosciences Holdings, Inc., Zynerba Pharmaceuticals, Inc. - M&A Call	23-08-14
Harmony Biosciences Agrees to Acquire Zynerba Pharmaceuticals	23-08-14	MT
Harmony Biosciences To Acquire Zynerba Pharmaceuticals, Inc.	23-08-14	RE
Zynerba Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Harmony Biosciences Holdings, Inc. entered into a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ) for $63.7 million.	23-08-13	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell Microcap Value Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell 3000E Value Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell 3000E Index	23-06-23	CI
Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from Russell Microcap Index	23-06-23	CI

Chart Zynerba Pharmaceuticals, Inc.

Duration

Period

More charts

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. The Company is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.80%	42.59B
MODERNA, INC.	+8.27%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.71%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.05%	18.17B
MEDPACE HOLDINGS, INC.	+28.65%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.04%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.07%	11.1B

Other Biotechnology & Medical Research